A Study in Healthy Subjects Designed to Evaluate the Pharmacokinetic Profile of Firibastat (QGC001) and Active Metabolites Following Administration of Firibastat (QGC001) Prototype Tablet Formulations
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2019
Price : $35 *
At a glance
- Drugs Firibastat (Primary) ; Firibastat
- Indications Chronic heart failure; Hypertension
- Focus Pharmacokinetics
- Sponsors Quantum Genomics
- 17 Jun 2019 Status changed from active, no longer recruiting to completed.
- 12 Jun 2019 Results presented in a Quantum Genomics media release.
- 25 Feb 2019 Status changed to active, no longer recruiting, according to a Quantum Genomics media release.